Evidence map›Paper›PMID 33858849›Full record

ArticleJournal for immunotherapy of cancer2021

Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model.

Peter M Carlson, Manasi Mohan, Matthew Rodriguez, Vladimir Subbotin, Claire X Sun, Ravi B Patel, Jen Birstler, Jacquelyn A Hank, Alexander L Rakhmilevich, Zachary S Morris and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. QuantifyingBiophotonics discovery · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cyclophosphamide augments the efficacy ofFrontiers in oncology · 2023
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Peter M Carlson *Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0003-1908-7233
Manasi Mohan *Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Matthew RodriguezDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Vladimir SubbotinDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Claire X SunDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ravi B PatelDepartment of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-8328-746X
Jen BirstlerDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jacquelyn A HankDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alexander L RakhmilevichDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Amy K ErbeDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Paul M SondelDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA pmsondel@humonc.wisc.edu.ORCID 0000-0002-0981-8875
University of Wisconsin–Madison · USUPMC Hillman Cancer Center · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2020 to 2024
$12.5M
INTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3M
NRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4M
Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9M
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sitesK08CA241319 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PATEL, RAVI BHASKER · 2019 to 2023
$629k
Molecular targeted radiotherapy to overcome resistance to in situ cancer vaccinationF30CA228315 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CARLSON, PETER M · 2019 to 2021
$102k
NCATS NIH HHS TL1 TR002375NCATS NIH HHS UL1 TR002373NCI NIH HHS F30 CA228315NCI NIH HHS K08 CA241319NCI NIH HHS P01 CA250972NCI NIH HHS R35 CA197078NCI NIH HHS U01 CA233100NCI NIH HHS U01 CA233102NCI NIH HHS U54 CA232568NIGMS NIH HHS T32 GM008692NIH HHS DP5 OD024576
6 · The paper itself

Abstract

An important component of research using animal models is ensuring rigor and reproducibility. This study was prompted after two experimenters performing virtually identical studies obtained different results when syngeneic B78 murine melanoma cells were implanted into the skin overlying the flank and treated with an in situ vaccine (ISV) immunotherapy. Although both experimenters thought they were using identical technique, we determined that one was implanting the tumors intradermally (ID) and the other was implanting them subcutaneously (SC). Though the baseline in vivo immunogenicity of tumors can depend on depth of their implantation, the response to immunotherapy as a function of tumor depth, particularly in immunologically 'cold' tumors, has not been well studied. The goal of this study was to evaluate the difference in growth kinetics and response to immunotherapy between identically sized melanoma tumors following ID versus SC implantation. We injected C57BL/6 mice with syngeneic B78 melanoma cells either ID or SC in the flank. When tumors reached 190-230 mm

Indexed as

ImmunotherapyAnimalsAntibodiesCancer VaccinesCell Line, TumorFemaleGangliosidesInjections, IntralesionalInterleukin-2KineticsMelanomaMiceMice, Inbred C57BLNeoplasm TransplantationRecombinant Fusion ProteinsSkin NeoplasmsAntibodiesCancer Vaccinesganglioside, GD2GangliosidesInterleukin-2Recombinant Fusion Proteinsimmunogenicityimmunologic techniquesimmunotherapymelanomatumor microenvironmentvaccine

Identifiers

PMID33858849
PMCPMC8055108
OpenAlexW3152521677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.